United Kingdom Contraceptive Drugs Market Insight
The United Kingdom Contraceptive Drugs market size is growing at a 4.25% CAGR, driven by increasing awareness of reproductive health, government-supported family planning initiatives, and wider access to contraception through the National Health Service. Rising demand for long-acting reversible contraceptives (LARCs) and ongoing innovation in hormonal formulations are further supporting market growth
United Kingdom Contraceptive Drugs Market Insights Forecasts to 2035
- The United Kingdom Contraceptive Drugs Market Size Was Estimated at USD 828.7 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 4.25% from 2025 to 2035
- The United Kingdom Contraceptive Drugs Market Size is Expected to Reach USD 1256.3 Million by 2035
Notable Insights for United Kingdom Contraceptive Drugs Market
- By product type, oral contraceptive pills dominated, accounting for approximately 45–50% share in 2024, contributing nearly USD 450–550 million, driven by widespread usage and easy accessibility.
- By hormone type, combined hormonal contraceptives dominated, holding approximately 55–60% share, contributing nearly USD 650–750 million, driven by high efficacy and widespread adoption among women of reproductive age in the UK.
- Approximately 70%+ of women in the UK use some form of contraception, reflecting strong awareness, accessibility, and widespread adoption supported by public healthcare services and national reproductive health programs.
- Nearly 30–35% rely on oral contraceptive pills, while the UK holds a significant share of the European contraceptive drugs market, driven by NHS access, education campaigns, and preventive healthcare initiatives.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Contraceptive Drugs market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Contraceptive Drugs Market
- Bayer AG
- Pfizer
- Organon & Co.
- Teva Pharmaceutical Industries
- Viatris
- Merck & Co.
- Others
Recent Developments:
- In March 2023, Drovelis (estetrol/drospirenone) was introduced in the UK as a new combined oral contraceptive, expanding modern hormonal options with a novel estrogen-based formulation to improve safety and tolerability.
- In January 2024, the UK approved extended use of Bayer’s Mirena (levonorgestrel IUS) for up to eight years for contraception, improving long-acting reversible contraceptive coverage and patient convenience.
Market Segmentation:
United Kingdom Contraceptive Drugs Market, By Product Type
- Oral Contraceptive Pills
- Injectable Contraceptives
- Topical Contraceptives
United Kingdom Contraceptive Drugs Market, By Hormone Type
- Combined Hormonal Contraceptives
- Progestin-only Contraceptives
United Kingdom Contraceptive Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Expert Views:
The UK Contraceptive Drugs Market is expected to grow steadily due to increasing awareness, supportive government policies, and improved accessibility through public healthcare systems. Experts highlight that over-the-counter contraceptives, long-acting formulations, and digital health integration will shape the market. As demand for safe and convenient birth control options rises, pharmaceutical companies focusing on innovation and accessibility will play a key role in advancing reproductive healthcare in the UK.